Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC)

Company Overview - Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on producing a drug to reduce cisplatin-induced ototoxicity (CIO) [1] - The drug is known as Pedmark in the US and Pedmarqsi in Europe, which is a sodium thiosulfate injection [1] Product Details - Cisplatin is a widely used chemotherapy drug that can cause hearing loss as a side effect, making the development of Pedmark/Pedmarqsi significant for patients undergoing treatment [1]